8-KOther Events

JOHNSON & JOHNSON 8-K Report, Corporate Update (Feb 7, 2007)

Filed February 7, 2007For Securities:JNJ

Summary

Johnson & Johnson (JNJ) announced on February 1, 2007, the successful closing of its acquisition of Conor Medsystems, Inc., a cardiovascular device company. This strategic move, valued at $1.4 billion, signals JNJ's intent to expand its presence in the cardiovascular device market, particularly leveraging Conor Medsystems' advanced controlled drug delivery technology. While the acquisition is expected to bolster JNJ's product portfolio and future growth prospects in a key healthcare segment, investors should note the immediate financial impact. The company anticipates a one-time after-tax charge of approximately $600 million, equating to $0.21 per share, primarily due to the write-off of in-process research and development. This charge will affect short-term earnings but is a common accounting consequence of acquiring companies with significant R&D assets.

Key Highlights

  • 1Johnson & Johnson has acquired Conor Medsystems, Inc., a cardiovascular device company, for $1.4 billion.
  • 2The acquisition aims to enhance JNJ's position in the cardiovascular device market.
  • 3Conor Medsystems possesses unique controlled drug delivery technology.
  • 4JNJ anticipates a one-time after-tax charge of approximately $600 million related to the acquisition.
  • 5This charge is estimated to reduce earnings per share by $0.21.
  • 6The charge is primarily attributed to the write-off of in-process research and development.

Frequently Asked Questions

The acquisition of Conor Medsystems is significant as it strengthens Johnson & Johnson's presence in the cardiovascular device market. Conor Medsystems' controlled drug delivery technology is a key asset that is expected to enhance JNJ's product offerings and innovation capabilities in this important therapeutic area.

Johnson & Johnson expects to incur a one-time after-tax charge of approximately $600 million as a result of the acquisition. This charge is largely due to the accounting requirement to write off in-process research and development assets acquired from Conor Medsystems.

The $600 million after-tax charge is expected to reduce Johnson & Johnson's earnings per share by approximately $0.21. This is a non-recurring charge and primarily reflects the accounting treatment for in-process R&D, not an ongoing operational cost.

Conor Medsystems is recognized for its unique controlled drug delivery technology. This specialized technology likely allows for more precise and sustained release of therapeutic agents, which can improve treatment efficacy and patient outcomes in cardiovascular applications.